Molecular target
Norepinephrine Transporter
Also: SLC6A2 · id NET
Reuptake transporter for norepinephrine. Targeted by SNRIs and certain TCAs.
Educational use only. This page summarizes published research and traditional-use records for educational purposes. It does not diagnose, treat, cure, or prevent any disease. Do not start, stop, or change medications based on this information. Discuss any decisions about therapies — pharmaceutical or botanical — with a qualified clinician who knows your medical history.
No PHI / HIPAA notice: Do not share Protected Health Information (PHI) of any patient on this site — including names, dates of birth, addresses, MRNs, or any identifying information. Use abstract case framing only. Sharing PHI with non-covered entities risks HIPAA violation regardless of platform capability.
Pharmaceutical agents
Drugs that act on Norepinephrine Transporter
These medications have Norepinephrine Transporter among their molecular targets. Sharing a target is a mechanistic relationship — it does not make any plant below an alternative to, or substitute for, these drugs.
Botanical connections
Plants whose compounds act on Norepinephrine Transporter
Each plant below contains a named compound documented to act on Norepinephrine Transporter. The compound and the reason for the connection are shown on every edge — a shared mechanism, not a therapeutic equivalence.
- CathinonePhenylalkylamine alkaloid
Primary psychoactive constituent; structurally and pharmacologically analogous to amphetamine. Research indicates it may promote monoamine release and inhibit reuptake at DAT, NET, and SERT, and may inhibit MAO-A and MAO-B. Degrades rapidly on storage, which is why leaves are chewed fresh.
- Cathine (norpseudoephedrine)Phenylalkylamine alkaloid
Less potent sympathomimetic than cathinone; may contribute to cardiovascular and appetite-suppressing effects reported in human chewing studies.
- HyperforinPhloroglucinol
Primary antidepressant constituent; inhibits SERT, NET, and DAT through a non-classical mechanism (TRPC6-mediated). Major source of CYP3A4 induction → drug-interaction profile.